Energy Efficiency, GHG Emissions, Industrial  -  November 17, 2023

SHL Medical Receives Approval From SBTi

SHL Medical, a provider of advanced drug delivery solutions, received approval from the Science Based Targets initiative (SBTi) for the company's near-term emissions targets.

The confirmed near-term targets include commits to reducing absolute direct (Scope 1) and indirect (scope 2) GHG emissions by 42% by 2030 from a 2022 baseline year.

SHL Medical also commits to reducing its indirect (Scope 3) GHG emissions by at least 51.6% per Mio. units sold by 2030 from a 2022 baseline year.

The result ranks SHL Medical in the top 8% in its industry, "manufacture of medical and dental instruments and supplies" and in the top 25% of all companies globally.  

"Our commitment towards sustainability is deeply ingrained in every facet of our operations," says Ulrich Faessler, CEO & Chairman of SHL Medical in a statement. "We are striving to be more transparent and accountable throughout our sustainability journey and I am proud to see independent recognition of our efforts so far, showing we are headed in the right direction. We know our responsibility extends beyond the immediate horizon, and we aim to contribute long-term value for society and the environment."

Share this valuable information with your colleagues using the buttons below: